Just this morning, Moderna (MRNA) was downgraded by JP Morgan on valuation concerns.

In fact, analyst Cory Kasimov said that while he is bullish on the stock, MRNA can no longer support the stock’s valuation.

On that news, MRNA fell $10.  However, the pullback may not last long thanks to strong COVID-19 study results.  Remember, not only ago, MRNA announced its vaccine was found to induce immune responses in every volunteer in a Phase 1 study.

“These early results, published in the New England Journal of Medicine on Tuesday, showed that the vaccine worked to trigger an immune response with mild side effects — fatigue, chills, headache, muscle pain, pain at the injection site — becoming the first US vaccine candidate to publish results in a peer-reviewed medical journal,” says CNN.

Plus, according to Investor’s Business Daily, “A midsize dose of the coronavirus vaccine generated several times more antibodies following a second injection than the level seen in patients who’ve already recovered from Covid-19. The presence of antibodies could indicate a person is immune to the virus.”

Now, the company is preparing to move into Phase 3 studies.   If it sees further success, MRNA could easily run to $100 a share.

But it’s not just MRNA that you should keep an eye on.

BioNTech (BNTX) and Pfizer (PFE)

The U.S. FDA “fast tracked” a vaccine in development with Pfizer and BioNTech.

According to BioNTech, two of the company’s four investigational candidates from its BNT162 mRNA-based program being developed to help protect against the virus were “fast tracked.”

Going forward, Pfizer and BioNTech expect to start the next phase of the vaccine trial later this month with 30,000 subjects.  If successful, the two expect to have 100 million doses of the vaccine by the close of 2020, and more than 1.2 billion by the end of 2021.

AstraZeneca (AZN) 

AZN should push higher on news a potential coronavirus vaccine developed by Oxford University in the U.K. with pharmaceutical giant AstraZeneca has produced a promising immune response in a large, early-stage human trial.